Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Update on the role of lenalidomide in patients with multiple myeloma
Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy
Therapeutic Advances in Hematology (2018) Vol. 9, Iss. 7, pp. 175-190
Open Access | Times Cited: 46

Showing 26-50 of 46 citing articles:

Invasive Orbital Squamous Cell Carcinoma in a Patient with Multiple Myeloma
Narges Karrabi, Kiana Hassanpour, Noushin Afshar Moghaddam, et al.
Case Reports in Ophthalmological Medicine (2022) Vol. 2022, pp. 1-5
Open Access | Times Cited: 7
Direct potentiation of NK cell cytotoxicity by 8-azaguanine with potential antineoplastic activity
Nayoung Kim, Jiwan Choi, Ahyoung Song, et al.
International Immunopharmacology (2018) Vol. 67, pp. 152-159
Closed Access | Times Cited: 11
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
Zachary J. Walker, Beau M. Idler, Lorraine N. Davis, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 3, pp. 819-830
Open Access | Times Cited: 9
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Katja Weisel, Ajay K. Nooka, Evangelos Terpos, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 8, pp. 1887-1896
Closed Access | Times Cited: 5
Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma
Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, et al.
Oncotarget (2020) Vol. 11, Iss. 44, pp. 3984-3997
Open Access | Times Cited: 7
Is autologous stem cell transplantation still relevant for multiple myeloma?
Taewoong Choi
Current Opinion in Hematology (2019) Vol. 26, Iss. 6, pp. 386-391
Closed Access | Times Cited: 5
Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
Ikhwan Rinaldi, Abdul Muthalib, Brenda Cristie Edina, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3507-3507
Open Access | Times Cited: 3
The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma
Yang Liu, Bo Li, Xiaohong Chen, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 1-3, pp. 47-54
Closed Access
Therapeutic advantage of combinatorial CAR T cell and chemo-therapies
Meghan B Ward, Amber B. Jones, Giedre Krenciute
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100011-100011
Open Access
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations from a Canadian Consensus Guideline Consortium
Sahar Khan, Debra Bergstrom, Julie Anne Côté, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Open Access
Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison
Faiz Anwer, Tommy Lan, Michael Dolph, et al.
Future Oncology (2024), pp. 1-10
Open Access
Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
Cătălin Constantinescu, Sergiu Pașca, Alina‐Andreea Zimța, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2903-2903
Open Access | Times Cited: 3
Lenalidomide with Dexamethasone to Multiple Myeloma Patients Relapsing from Bortezomib-Based Induction Therapies: a Prospective, Observational Study
Tran‐Der Tan, Ying-Chung Hong, Sin‐Syue Li, et al.
The Chinese Journal of Physiology (2020) Vol. 63, Iss. 5, pp. 211-217
Open Access | Times Cited: 3
An Updated Comprehensive Pharmacovigilance Study of Drug‐Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data
Li Kun-yu, Shi Shuping, Chang Su, et al.
The Journal of Clinical Pharmacology (2023) Vol. 64, Iss. 4, pp. 478-489
Closed Access | Times Cited: 1
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
Gregorio Barilà, Laura Pavan, Susanna Vedovato, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 3
Synthesis and antitumor activity of a series of novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones derivatives
Bin Li, Mingli Hu, Chen Chen, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 73, pp. 128919-128919
Closed Access | Times Cited: 2
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide
Barbara Gamberi, Christian Berthou, Miguel‐Teodoro Hernández, et al.
Clinical Lymphoma Myeloma & Leukemia (2020) Vol. 20, Iss. 10, pp. e629-e644
Open Access | Times Cited: 1
Determination of Possible Potential Genotoxic Impurities in Lenalidomide Drug Substance by Simple RP-HPLC Method
Kishore Gaddam, Shanker Kanne, Trivikram Reddy Gundala, et al.
Asian Journal of Chemistry (2020) Vol. 32, Iss. 12, pp. 2965-2970
Open Access
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome
Meral Beksaç, Güldane Cengiz Seval, Derya Koyun, et al.
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 23, Iss. 3, pp. e164-e170
Open Access
Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Effectivity and Adverse Events
Ali Zahit Bolaman, Atakan Turgutkaya, Birsen Sahip, et al.
Turkish Journal of Hematology (2021)
Open Access
Previous Page - Page 2

Scroll to top